Pathologic characteristics of soft tissue and osseous metastases

Neil A. Abrahams, Alberto Ayala

Research output: Chapter in Book/Report/Conference proceedingChapter


Of the one in six men expected to develop prostate cancer over a lifetime period,2 35% to 40% of these patients are expected to eventually experience a rise in serum prostate-specific antigen (PSA) signaling either local or metastatic spread.5 Within the subgroup of patients with metastatic disease, bone metastases are considered the hallmark of advanced prostate cancer. The paradox with prostate cancer is that while the incidence of prostate cancer in both North America and Europe has increased, in part due to PSA screening, the mortality rate has remained fairly stable.1,3,4,6 The low death rate indicates that many men are alive long after the initial diagnosis of prostate cancer, and a significant proportion of these patients, after a relatively long latency period, develop both soft tissue and osseous metastases.

Original languageEnglish (US)
Title of host publicationProstate Cancer
Subtitle of host publicationPrinciples and Practice
PublisherCRC Press
Number of pages9
ISBN (Electronic)9780203624326
ISBN (Print)9781841844589
StatePublished - Jan 1 2005

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Pathologic characteristics of soft tissue and osseous metastases'. Together they form a unique fingerprint.

Cite this